Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621369 | 0.97 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621342 | 0.97 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70761 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621378 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70762 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621382 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28854682 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL25973965 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5747789 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5747781 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9365602-B2 | Sodium glucose co-transporter inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-05-15 | — | — | US | disclosed |
| US-8476413-B2 | Sulfanyl-tetrahydropyran-based compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-12-09 | — | — | US | disclosed |
| US-7846945-B2 | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | SLC2A1, SLC2A2, SLC5A2 | SMN1; SMN2 3414/4885NPC1 94/4885RAB9A 2405/4885 |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SMN1; SMN2 3100/4885NPC1 95/4885RAB9A 2029/4885 |
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SMN1; SMN2 3100/4885NPC1 95/4885RAB9A 2029/4885 |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | GPR119, FABP4, LIPC | SMN1; SMN2 1482/4885NPC1 949/4885RAB9A 1961/4885 |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SMN1; SMN2 3100/4885NPC1 95/4885RAB9A 2029/4885 |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | SLC2A1, SLC2A2, SLC5A2 | SMN1; SMN2 3414/4885NPC1 94/4885RAB9A 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.